EHAB vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EHAB exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the stock has seen a significant 1-year price surge (+78.4%), this momentum is disconnected from core profitability, as evidenced by a negative profit margin (-0.43%) and negative ROE (-0.46%). The lack of a Graham Number and the absence of an Altman Z-Score, combined with bearish insider selling, suggest a speculative valuation. The recent price action likely reflects merger speculation mentioned in SEC filings rather than organic growth.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
EHAB vs MRK: Head-to-Head Comparison
This page compares Enhabit, Inc. (EHAB) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.